banner
p38-MAPK inhibitor TAK-715, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ887

p38-MAPK inhibitor TAK-715, Purity ≥98%

Synonym: TAK-715; 303162-79-0; TAK 715; N-(4-(2-ethyl-4-(m-tolyl)thiazol-5-yl)pyridin-2-yl)benzamide; TAK715; R-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]-Benzamide; p38-MAPK inhibitor

  • MDL: MFCD17012805
  • CAS Number: 303162-79-0
  • Compound CID: 9952773
img
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
TAK-715, soluble in DMSO and ethanol and insoluble in water, targets the ATP-binding site of the kinase, thereby preventing phosphorylation of downstream substrates. It targets ERK1, IKKβ, JNK1, and MEKK1.
Molecular Weight
399.51
Molecular Formula
C24H21N3OS
Targets
ERK1: >10 μM; IKKβ: >10 μM; JNK1: >10 μM; MEKK1: >10 μM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 72 mg/mL (180.22 mM); Water: Insoluble; Ethanol: 14 mg/mL (35.04 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
TAK-715 can be used to study p38 MAP kinase inhibition and its effects on inflammatory disease models.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0